N
Nan Xiao
Researcher at Fudan University
Publications - 6
Citations - 59
Nan Xiao is an academic researcher from Fudan University. The author has contributed to research in topics: Cytotoxic T cell & Tumor microenvironment. The author has an hindex of 2, co-authored 5 publications receiving 13 citations.
Papers
More filters
Journal ArticleDOI
NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma.
Kang-Shuai Li,Xiao-Dong Zhu,Hongda Liu,Shi-Zhe Zhang,Xiao-Long Li,Nan Xiao,Xue-Feng Liu,Bin Xu,Ming Lei,Yuan-Yuan Zhang,Wen-Kai Shi,Man-Qing Cao,Yunfei Xu,Zhao-You Tang,Hui-Chuan Sun +14 more
TL;DR: It is demonstrated for the first time that NT5DC2 promotes tumor cell proliferation in HCC and may serve as a potential molecular target for treating HCC.
Journal ArticleDOI
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma.
Nan Xiao,Xiao-Dong Zhu,Kangshuai Li,Yifan Chen,Xue-Feng Liu,Bin Xu,Ming Lei,Jiejie Xu,Hui-Chuan Sun +8 more
TL;DR: Wang et al. as discussed by the authors showed that Siglec-10 was abundant in a large proportion of hepatocellular carcinoma (HCC) specimens and prominently distributed on macrophages.
Journal ArticleDOI
CD74+ macrophages are associated with favorable prognosis and immune contexture in hepatocellular carcinoma
TL;DR: Wang et al. as discussed by the authors found that stromal CD74+ cell enrichment was associated with favorable prognosis in patients with hepatocellular carcinoma (HCC) and showed that blocking CD74 weakened the antitumor activity and proliferation ability of CD8+ CTLs in HCC.
Journal ArticleDOI
A prospective study of the effect of terlipressin on portal vein pressure and clinical outcomes after hepatectomy: A pilot study.
Xiao-Long Li,Xiao-Dong Zhu,Nan Xiao,Xue-Feng Liu,Bin Xu,Guo-Ming Shi,Cheng Huang,Ying-Hao Shen,Jia-Bin Cai,Jian Zhou,Jia Fan,Hui-Chuan Sun +11 more
TL;DR: Tepid portal vein pressure is decreased and terlipressin may decrease the incidence of posthepatectomy liver failure and postoperative abdominal drainage (NCT03352349); acute kidney injury, operative complications, and side-effects were not different between groups.
Journal ArticleDOI
Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model
Xue-Feng Liu,Xiao-Dong Zhu,Long Feng,Xiao-Long Li,Bin Xu,Nan Xiao,Ming Lei,Hui-Chuan Sun,Zhao-You Tang +8 more
TL;DR: In this paper , the authors investigated the hypothesis that physical activity synergizes with combined lenvatinib plus anti-PD-1 therapy to enhance efficacy in patients with unresectable HCC.